Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
31 Jan 2023
Historique:
entrez: 23 1 2023
pubmed: 24 1 2023
medline: 26 1 2023
Statut: ppublish

Résumé

The majority of pathogenic mutations in the neurofibromatosis type I (

Identifiants

pubmed: 36689660
doi: 10.1073/pnas.2208960120
pmc: PMC9945959
doi:

Substances chimiques

Neurofibromin 1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2208960120

Subventions

Organisme : NCI NIH HHS
ID : R35 CA197709
Pays : United States
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States

Références

Hum Genet. 2017 Apr;136(4):349-376
pubmed: 28213670
Acta Crystallogr D Struct Biol. 2021 Oct 1;77(Pt 10):1282-1291
pubmed: 34605431
Hum Mutat. 2015 Nov;36(11):1052-63
pubmed: 26178382
Hum Mol Genet. 2016 May 1;25(9):1703-13
pubmed: 26908603
Lab Invest. 2016 Oct;96(10):1105-15
pubmed: 27617404
Hum Mutat. 2020 Jan;41(1):299-315
pubmed: 31595648
Genet Med. 2019 Apr;21(4):867-876
pubmed: 30190611
Am J Hum Genet. 2007 Jan;80(1):140-51
pubmed: 17160901
J Struct Biol. 2015 Nov;192(2):216-21
pubmed: 26278980
Nat Struct Mol Biol. 2021 Dec;28(12):982-988
pubmed: 34887559
Nat Rev Dis Primers. 2017 Feb 23;3:17004
pubmed: 28230061
Dev Cell. 2011 Dec 13;21(6):1062-76
pubmed: 22118770
Cell. 1990 Nov 16;63(4):843-9
pubmed: 2121370
J Mol Neurosci. 2014 Jun;53(2):204-10
pubmed: 24676943
J Am Acad Dermatol. 2010 Sep;63(3):440-7
pubmed: 20605257
Virology. 2013 Feb 5;436(1):49-58
pubmed: 23123012
Medicine (Baltimore). 2011 May;90(3):201-211
pubmed: 21512413
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
J Clin Invest. 2018 Jul 2;128(7):2848-2861
pubmed: 29596064
J Biol Chem. 2020 Jan 24;295(4):1105-1119
pubmed: 31836666
Mol Cell. 2022 Apr 7;82(7):1288-1296.e5
pubmed: 35353986
J Med Genet. 2019 Apr;56(4):209-219
pubmed: 30530636
Cancer Discov. 2013 Aug;3(8):880-93
pubmed: 23661552
Hum Mutat. 2022 Jan;43(1):30-41
pubmed: 34694046
Hum Genomics. 2017 Jun 21;11(1):13
pubmed: 28637487
Genes Dev. 2012 Jul 1;26(13):1421-6
pubmed: 22751498
Nat Methods. 2013 Jun;10(6):584-90
pubmed: 23644547
Mol Cancer Res. 2019 May;17(5):1220-1232
pubmed: 30705246
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
Childs Nerv Syst. 2020 Oct;36(10):2443-2452
pubmed: 32607696
Elife. 2018 Nov 09;7:
pubmed: 30412051
Dis Model Mech. 2016 Jul 1;9(7):759-67
pubmed: 27482814
Am J Hum Genet. 2018 Jan 4;102(1):69-87
pubmed: 29290338
Nat Rev Mol Cell Biol. 2019 Nov;20(11):665-680
pubmed: 31253954
Nature. 2021 Nov;599(7884):315-319
pubmed: 34707296
Orphanet J Rare Dis. 2018 Feb 07;13(1):31
pubmed: 29415745
Annu Rev Genomics Hum Genet. 2013;14:355-69
pubmed: 23875798

Auteurs

Lucy C Young (LC)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.

Ruby Goldstein de Salazar (R)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.

Sae-Won Han (SW)

Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.

Zi Yi Stephanie Huang (ZYS)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.

Alan Merk (A)

National Cryo-EM Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.

Matthew Drew (M)

National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.

Joseph Darling (J)

National Cryo-EM Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.

Vanessa Wall (V)

National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.

Reinhard Grisshammer (R)

National Cryo-EM Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.

Alice Cheng (A)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.

Madeline R Allison (MR)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.

Matthew J Sale (MJ)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.

Dwight V Nissley (DV)

National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.

Dominic Esposito (D)

National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.

Jana Ognjenovic (J)

National Cryo-EM Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.

Frank McCormick (F)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH